DermaGenoma, a molecular dermatology research and development company, has made PsoriasisDX Genetic Test for Psoriatic Arthritis (PsA) available as a CE marked product under the European In Vitro Diagnostic (IVD) Directive.

DermaGenoma said that the CE marking is required for certain product groups to indicate conformity with the essential requirements set out in European Directives. The PsoriasisDX Genetic Test for Psoriatic Arthritis complies with the essential requirements of the European IVD Directive.

DermaGenoma said that PsoriasisDX Genetic Test helps identify those at high risk for developing Psoriatic Arthritis before they experience arthritic symptoms, providing the opportunity to lessen joint damage through early medical intervention.

Andy Goren, CEO of DermaGenoma, said: “We are excited to extend this revolutionary genetics testing breakthrough to dermatologists in Europe. It helps doctors determine the proper treatments for patients.”